(Sharecast News) - GSK said on Thursday that late-stage trial results for its experimental drug for chronic hepatitis B, bepirovirsen, showed that it helped nearly one in five patients to achieve a functional cure.
Bepirovirsen is an investigational antisense oligonucleotide (ASO) designed to recognise and inhibit the production of the genetic...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE